Interim Data From TID Trial Are Positive
Source: Streetwise Reports  (5/15/25)
Sernova Biotherapeutics Inc.'s (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) regenerative treatment delivered via its Cell Pouch Bio-hybrid Organ is proving to result in insulin independence, among other outcomes. Read what one analyst says are the implications of this clear medical benefit. More >

Biotech Firm Unlocks Alzheimer's Market with U.S. Clinic Launch
Source: Streetwise Reports  (5/13/25)
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) has acquired NoBrainer Imaging, unlocking Alzheimer's PET scan clinics in Florida, Los Angeles, five select U.S. cities, and Canada. Read more to explore the growth potential. More >

Biopharma Receives PDUFA Date for Lead Program
Source: Jason Kolbert  (5/9/25)
This is a critical milestone for the company and significant for the space given the lack of approved therapies, noted a D. Boral Capital report. More >

Biopharma Shares Efficacy Data at AUA Meeting
Source: Dr. Leland Gershell  (5/1/25)
These results and input from key opinion leaders boost "our enthusiasm for this candidate's prospects as a treatment for non-muscle, invasive bladder cancer, noted an Oppenheimer report. More >

New Cell Treatment for Bladder Cancer Shows Promise
Source: Dr. Andres Maldonado  (5/1/25)
This investigative therapy is "uniquely positioned to occupy a distinct segment" within the evolving and crowded space, noted an H.C. Wainwright & Co. report. More >

Biotech Co. Achieves Remarkable Cancer Treatment Results in Trial
Source: Streetwise Reports  (4/29/25)
Clinical-stage biopharmaceutical company Protara Therapeutics Inc. (TARA:NASDAQ) announces updated results from its trials of a drug for high-risk non-muscle invasive bladder cancer (NMIBC). Read why analysts are recommending this biopharmaceutical stock. More >

One Co. With Cell Holding Device Stands Out in T1D Space
Source: Dr. Joseph Pantginis  (4/28/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) alone has shown favorable outcomes in a trial when patients with this disease were treated with an implanted device containing donor islets, noted an H.C. Wainwright & Co. report. More >

Biotech Firm Uncovers Long-Term Cancer Breakthrough in Nevada
Source: Streetwise Reports  (4/28/25)
UroGen Pharma Ltd. (URGN:NASDAQ) unveiled nearly four years of durable response for JELMYTO in Nevada, offering a breakthrough for low-grade upper tract cancer patients. See how UroGen Pharmas breakthrough data could reshape non-surgical cancer treatments and drive future growth in the oncology sector.

More >

Biotech Company Reports Promising Neurological Treatment in Clinical Study
Source: Streetwise Reports  (4/25/25)
Clinical-stage biotechnology company Coya Therapeutics Inc. (COYA:NASDAQ) announces positive interim results of a study for the treatment of patients with frontotemporal dementia (FTD). Read to see what catalysts one analyst said the stock can look forward to this year. More >

Biopharma Company Leverages AI-Powered Platform for Cancer Breakthroughs
Source: Streetwise Reports  (4/24/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) announced its scientific advisor and collaborator Dr. Artem Cherkasov was recently recognized as a leader in AI-driven drug development. Find out which analysts recently initiated coverage on the company. More >

Biotech Discovers Revolutionary Immunotherapy in Houston
Source: Jason Kolbert  (4/24/25)
Coya Therapeutics Inc. (COYA:NASDAQ) recently reported a statistically significant Treg improvement in FTD patients with its dual-action immunotherapy, showing promising neuroprotection, according to a D. Boral research note. More >

Analyst Reveals Undervalued Pharmaceutical Gem in Canada
Source: Dr. Douglas Loe  (4/14/25)
In a recent research note from Leede Financial Inc. analyst Dr. Douglas Loe said Theratechnologies Inc. (TH:TSX; THTX:NASDAQ) has long term potential. More >

New Drug for Early AD Shown to be Efficacious, Safe
Source: Jason Kolbert  (4/9/25)
Trial participants exhibited improvements in cognitive function and activities of daily living, noted a D. Boral Capital report. More >

Rest of 2025 Rich With Catalysts for Immunotherapy Co.
Source: Jason Kolbert  (4/9/25)
These anticipated events will advance the oncology firm's lead candidate, for lung-only metastatic osteosarcoma, toward commercialization, noted a D. Boral Capital report. More >

Four-Year Data on New Drug for Early AD Positive
Source: Dr. Ram Selvaraju  (4/9/25)
Long-term treatment with this small molecule seems feasible given its safety and tolerability profile, noted an H.C. Wainwright & Co. report. More >

Share Price Appreciation of Biotech Due Over Next Six Months
Source: Dr. David Nierengarten  (4/8/25)
Given its robust pipeline, numerous milestones for this Outperform-rated company are slated to occur in the near-term, noted a Wedbush report. More >

New Therapy for AATD Could be Best in Class
Source: Patrick Trucchio  (4/8/25)
Updated trial data show it to be safe and efficacious and have a dual mechanism of action, noted an H.C. Wainwright & Co. report. More >

Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal
Source: Streetwise Reports  (4/8/25)
Beam Therapeutics Inc. (BEAM:NASDAQ) shows strong momentum with positive analyst ratings and new data from its BEAM-302 trial in AATD. Find out why experts see major upside potential. More >

Biotech Co. Has Promising AI-Accelerated Pipeline
Source: Alexander Rihane  (4/7/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) recently gained analyst coverage from First Berlin Equity Research. Read on to see why this company rates the stock a Buy. More >

Immunotherapy Company Finds Rare Cancer Breakthrough in U.S.
Source: Streetwise Reports  (4/7/25)
OS Therapies Inc. (OSTX:NYSEAMERICAN) announced that its lead drug OST-HER2 was granted Orphan Drug Designation by the FDA for osteosarcoma. Read how the designation could accelerate development and create new investor interest. More >

Biotech Company Finds High-Impact Alzheimer's Therapy in Europe
Source: Streetwise Reports  (4/7/25)
Anavex Life Sciences Corp. (AVXL:NASDAQ) earned positive analyst coverage following new long-term data for blarcamesine in early Alzheimer's disease. Experts pointed to safety, durability, and potential approval pathways. Read more about what they said. More >

Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results
Source: Streetwise Reports  (4/4/25)
Reviva Pharmaceuticals Holdings Inc. (RVPH: NASDAQ) is gaining attention with strong Phase 3 results for its lead CNS candidate, brilaroxazine. Here's what analysts are seeing in its long-term potential. More >

Regenerative Medicine Firm OK'd To Advance Trial in T1D
Source: Streetwise Reports  (4/3/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says the Data Safety Monitoring Board supports the ongoing evaluation of the biotech's Cell Pouch Bio-hybrid Organ in this indication. More >

Cell Pouch Co. Peer Aborts Program Using Like Device
Source: Dr. Douglas Loe  (4/3/25)
The implications for Cell Pouch, an implantable cell delivery vehicle, and the biotech behind it are positive, noted a Leede Financial Inc. report. More >

Ascending Dose Trial of FABP5 Inhibitor to Read Out Soon
Source: Jason Kolbert  (4/3/25)
Meanwhile, a representative from the company advancing the small molecule in the clinic is slated to speak about it at a conference this week, noted a D. Boral Capital report. More >